Home > Investor Relations > Financial Results > Latest Results

Latest Results

February 1, 2018

FY2017 Full Year Consolidated Financial Overview

Financial Highlight (IFRS)

Consolidated Statements of Income

(millions of yen, rounded to the nearest one million yen)

Revenues Cost of sales Marketing and distribution Research and development General and administration
534,199 (254,171) (72,800) (92,947) (15,347)
Operating profit Operating profit ratio (%) Profit before taxes Net income Basic Earnings per share (Yen)
98,934 18.5 97,031 73,541 133.04

Consolidated Balance Sheets

(millions of yen, rounded to the nearest one million yen)

Total assets Total non-current assets Total current assets Total non-current liabilities Total current liabilities
852,473 253,333 599,141 (36,674) (122,902)
Capital and reserves attributable to Chugai shareholders Investment on property, plant and equipment (billion yen) Equity ratio attributable to Chugai shareholders (%) Annual dividends per share (yen) Interim dividends per share (yen)
691,924 34.3 81.2 62.00 33.00

Revenues: 534.2 billion JPY (+42.4, +8.6% YoY)

Domestic sales excl. Tamiflu®: increase as growth of mainstay products exceeded impact of HIP revision (+8.7, +2.3%)
Overseas sales: growth of Alecensa® export to Roche, etc. (+14.5, +18.2%)
Royalties and other operating income: increase in milestone income (+15.8, +82.7%)

Cost of sales / Operating expenses (Core basis)

Cost of sales: the ratio to sales improved due to change in product mix, etc. (-1.5% points, from 52.2% to 50.7%)
Operating expenses: increase in marketing and distribution expenses, research and development expenses, and general and administration expenses, etc. (-13.6, +8.3%)

Profits

IFRS results:  
operating profit  98.9 billion JPY (+22.0, +28.6%)
net income  73.5 billion JPY (+19.1, +35.1%)
Core results:  
operating profit  103.2 billion JPY (+22.6, +28.0%)
net income  76.7 billion JPY (+19.9, +35.0%)
EPS  138.68 JPY (+36.18, +35.3%)

Jan-Sep 2017 Sales excluding Tamiflu®

Core Operating Income Jan-Sep

*Amounts are rounded to the nearest 0.1 billion yen.
Variance and % are calculated based on amounts shown.

To view PDF files,
you will need Adobe® Reader® which is available as a free download.